Lactobacillus plantarum MYL26 induces endotoxin tolerance phenotype in Caco-2 cells

BMC Microbiology

Research Article

Chin-Chi Tsai¹  Meei-Yn Lin¹  Yi-Heng Chiu¹  Chien-Tsai Huang¹  Chu-Chyn Ou²  Ying-Chen Lu³  Shiao-Lin Lin⁴ 

[1] Department of Food Science and Biotechnology, National Chung Hsing University, 250 Kuokuang Road, 40227, Taichung, Taiwan;Department of Food Science and Biotechnology, National Chung Hsing University, 250 Kuokuang Road, 40227, Taichung, Taiwan;School of Nutrition, Chung Shan Medical University, Taichung, Taiwan;Department of Nutrition, Chung Shan Medical University Hospital, Taichung, Taiwan;Department of Food Science, National Chiayi University, Chiayi City, Taiwan;Department of Neurology, Chong Guang Hospital, MiaoLi County, Taiwan;

关键词: Lactobacillus plantarum;    Lipopolysaccharide;    Caco-2 cells;   

DOI  :  10.1186/1471-2180-13-190

 received in 2012-11-21, accepted in 2013-08-06,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundCrohn's disease and ulcerative colitis are the major types of chronic inflammatory bowel disease occurring in the colon and small intestine. A growing body of research has proposed that probiotics are able to attenuate the inflammatory symptoms of these diseases in vitro and in vivo. However, the mechanism of probiotic actions remains unclear.ResultsOur results suggested Lactobacillus plantarum MYL26 inhibited inflammation in Caco-2 cells through regulation of gene expressions of TOLLIP, SOCS1, SOCS3, and IκBα, rather than SHIP-1 and IRAK-3.ConclusionsWe proposed that live/ heat-killed Lactobacillus plantarum MYL26 and bacterial cell wall extract treatments impaired TLR4-NFκb signal transduction through Tollip, SOCS-1 and SOCS-3 activation, thus inducing LPS tolerance. Our findings suggest that either heat-killed probiotics or probiotic cell wall extracts are able to attenuate inflammation through pathways similar to that of live bacteria.

【 授权许可】

Unknown   
© Chiu et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.